Delivery Order SPE2DB22D1106-SPE2DB25FEWY9
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,892.67 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract. The award was issued on March 11, 2025, with an ultimate completion date of March 12, 2025, and represents a non-set-aside competitive award. Performance will be executed from the contractor's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,927.86. The order was competitively awarded without set-aside designation and is scheduled for completion by July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location and serve as the prime contractor on this delivery order, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) with a contract value of $6,400.76. This competitively awarded, firm fixed price delivery order was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) valued at $1,783.60 with a firm fixed price structure. This competitively awarded, non-set-aside contract is a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The order is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,367.16. The award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,609.67 to AmerisourceBergen Drug Corp for Vyvanse 20 mg capsules (100 count) on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price delivery order, issued with no set-aside designation, is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader contracting...
- The Defense Logistics Agency awarded a delivery order valued at $2,571.30 to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed-price contract. The award was made competitively with no set-aside designation and carries an ultimate completion date of September 8, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its Corporate Office location in the same municipality. This delivery...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEWY9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) valued at $7,563.09. The contract is a firm fixed-price delivery order with an ultimate completion date of July 10, 2025, following the award date of July 9, 2025. This award was made without set-aside designation, indicating competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfills the delivery at its corporate office location in the same city. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor supporting the DLA Medical Supply Chain, AmerisourceBergen supplies critical pharmaceutical products to military healthcare systems and federal medical procurement programs. The company's extensive federal contract portfolio demonstrates consistent capability in delivering both brand-name and generic medications across diverse therapeutic domains, including neurological treatments such as Vyvanse, to support defense and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 7/9/25 |